Using parallelized incremental meta-docking can solve the conformational sampling issue when docking large ligands to proteins
Tóm tắt
Docking large ligands, and especially peptides, to protein receptors is still considered a challenge in computational structural biology. Besides the issue of accurately scoring the binding modes of a protein-ligand complex produced by a molecular docking tool, the conformational sampling of a large ligand is also often considered a challenge because of its underlying combinatorial complexity. In this study, we evaluate the impact of using parallelized and incremental paradigms on the accuracy and performance of conformational sampling when docking large ligands. We use five datasets of protein-ligand complexes involving ligands that could not be accurately docked by classical protein-ligand docking tools in previous similar studies. Our computational evaluation shows that simply increasing the amount of conformational sampling performed by a protein-ligand docking tool, such as Vina, by running it for longer is rarely beneficial. Instead, it is more efficient and advantageous to run several short instances of this docking tool in parallel and group their results together, in a straightforward parallelized docking protocol. Even greater accuracy and efficiency are achieved by our parallelized incremental meta-docking tool, DINC, showing the additional benefits of its incremental paradigm. Using DINC, we could accurately reproduce the vast majority of the protein-ligand complexes we considered. Our study suggests that, even when trying to dock large ligands to proteins, the conformational sampling of the ligand should no longer be considered an issue, as simple docking protocols using existing tools can solve it. Therefore, scoring should currently be regarded as the biggest unmet challenge in molecular docking.
Tài liệu tham khảo
van Montfort RL, Workman P. Structure-based drug design: Aiming for a perfect fit. Essays Biochem. 2017; 61(5):431–7.
Nero TL, Parker MW, Morton CJ. Protein structure and computational drug discovery. Biochem Soc Trans. 2018; 46(5):1367–79.
Muhammed MT, Aki-Yalcin E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem Biol Drug Des. 2019; 93(1):12–20.
Ceska T, Chung C-W, Cooke R, Phillips C, Williams PA. Cryo-EM in drug discovery. Biochem Soc Trans. 2019.
McCarthy MJ, Pagba CV, Prakash P, Naji AK, van der Hoeven D, Liang H, Gupta AK, Zhou Y, Cho K-J, Hancock JF, Gorfe AA. Discovery of high affinity non-covalent allosteric KRAS inhibitors that disrupt effector binding. ACS Omega. 2019; 4(2):2921–30.
Antunes DA, Devaurs D, Kavraki LE. Understanding the challenges of protein flexibility in drug design. Exp Op Drug Disc. 2015; 10(12):1301–13.
Gupta AK, Wang X, Pagba CV, Prakash P, Sarkar-Banerjee S, Putkey J, Gorfe AA. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate. Chem Biol Drug Design. 2019; 94(2):1441–1456. Online early view.
Guedes IA, de Magalhães CS, Dardenne LE. Receptor-ligand molecular docking. Biophys Rev. 2014; 6(1):75–87.
Grinter SZ, Zou X. Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design. Molecules. 2014; 19(7):10150–76.
Sousa SF, Ribeiro AJ, Coimbra JT, Neves RP, Martins SA, Moorthy NS, Fernandes PA, Ramos MJ. Protein-ligand docking in the new millennium - A retrospective of 10 years in the field. Curr Med Chem. 2013; 20(18):2296–314.
Dhanik A, McMurray JS, Kavraki LE. DINC: A new AutoDock-based protocol for docking large ligands. BMC Struct Biol. 2013; 13(Suppl 1):11.
Weill N, Therrien E, Campagna-Slater V, Moitessier N. Methods for docking small molecules to macromolecules: A user’s perspective. 1. The theory. Curr Pharm Des. 2014; 20(20):3338–59.
Bello M, Martínez-Archundia M, Correa-Basurto J. Automated docking for novel drug discovery. Exp Op Drug Disc. 2013; 8(7):821–834.
Chaput L, Mouawad L. Efficient conformational sampling and weak scoring in docking programs? Strategy of the wisdom of crowds. J Cheminform. 2017; 9(1):37.
Antunes DA, Abella JR, Devaurs D, Rigo MM, Kavraki LE. Structure-based methods for binding mode and binding affinity prediction for peptide-MHC complexes. Curr Top Med Chem. 2018; 18(26):2239–55.
Gupta M, Sharma R, Kumar A. Docking techniques in pharmacology: How much promising?. Comput Biol Chem. 2018; 76:210–7.
Dhanik A, McMurray JS, Kavraki LE. AutoDock-based incremental docking protocol to improve docking of large ligands. In: Proc. IEEE BIBM Workshops. Piscataway: IEEE: 2012. p. 48–55.
Dhanik A, McMurray JS, Kavraki LE. Binding modes of peptidomimetics designed to inhibit STAT3. PLoS ONE. 2012; 7(12):51603.
Mandal PK, Morlacchi P, Knight JM, Link TM, Lee IV GR, Nurieva R, Singh D, Dhanik A, Kavraki LE, Corry DB, Ladbury JE, McMurray JS. Targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics potently inhibits Tyr641 phosphorylation and transcriptional activity. J Med Chem. 2015; 58(22):8970–84.
Antunes DA, Devaurs D, Moll M, Lizée G, Kavraki LE. General prediction of peptide-MHC binding modes using incremental docking: A proof of concept. Sci Rep. 2018; 8:4327.
Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31(2):455–61.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785–91.
Antunes DA, Moll M, Devaurs D, Jackson KR, Lizée G, Kavraki LE. DINC 2.0: A new protein-peptide docking webserver using an incremental approach. Cancer Res. 2017; 77(21):55–57.
Kavraki LE, et al.DINC Web Server. http://dinc.kavrakilab.org.
Wang Z, Sun H, Yao X, Li D, Xu L, Li Y, Tian S, Hou T. Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: The prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys. 2016; 18(18):12964–75.
Hauser AS, Windshügel B. LEADS-PEP: A benchmark data set for assessment of peptide docking performance. J Chem Inf Model. 2016; 56(1):188–200.
Rentzsch R, Renard BY. Docking small peptides remains a great challenge: An assessment using AutoDock Vina. Brief Bioinform. 2015; 16(6):1045–56.
Agrawal P, Singh H, Srivastava HK, Singh S, Kishore G, Raghava GP. Benchmarking of different molecular docking methods for protein-peptide docking. BMC Bioinform. 2019; 19(Suppl 13):426.
Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015; 10(5):449–61.
Cantú-Paz E, Goldberg DE. Are multiple runs of genetic algorithms better than one?. In: Proc. GECCO. New York: Springer: 2003. p. 801–12.
da Silva ML, Gonçalves A. d., Batista P. R., Figueroa-Villar J. D., Pascutti P. G., França T. C.Design, docking studies and molecular dynamics of new potential selective inhibitors of Plasmodium falciparum serine hydroxymethyltransferase. Mol Simul. 2010; 36(1):5–14.
Yang Z, Nie Y, Yang G, Zu Y, Fu Y, Zhou L. Synergistic effects in the designs of neuraminidase ligands: Analysis from docking and molecular dynamics studies. J Theor Biol. 2010; 267(3):363–74.
Wang X, Yang W, Xu X, Zhang H, Li Y, Wang Y. Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr Med Chem. 2010; 17(25):2788–803.
Sokkar P, Sathis V, Ramachandran M. Computational modeling on the recognition of the HRE motif by HIF-1: Molecular docking and molecular dynamics studies. J Mol Model. 2012; 18(5):1691–700.
Machado KS, Winck AT, Ruiz DD, de Souza ON. Mining flexible-receptor docking experiments to select promising protein receptor snapshots. BMC Genomics. 2010; 11(Suppl 5):6.
Nichols SE, Baron R, Ivetac A, McCammon JA. Predictive power of molecular dynamics receptor structures in virtual screening. J Chem Inf Model. 2011; 51(6):1439–46.
Martinez-Ramos F, Fonseca-Sabater Y, Soriano-Ursúa MA, Torres E., Rosales-Hernandez MC, Trujillo-Ferrara JG, Tolentino-Lopez LE, Ian I-F, Correa-Basurto J. o-Alkylselenenylated benzoic acid accesses several sites in serum albumin according to fluorescence studies, Raman spectroscopy and theoretical simulations. Protein Pept Lett. 2013; 20(6):705–14.
Rocchia W, Masetti M, Cavalli A. Enhanced sampling methods in drug design In: Luque J, Barril X., editors. Physico-Chemical and Computational Approaches to Drug Discovery. Cambridge: The Royal Society of Chemistry: 2012. p. 273–301.
Sinko W, Lindert S, McCammon JA. Accounting for receptor flexibility and enhanced sampling methods in computer-aided drug design. Chem Biol Drug Des. 2013; 81(1):41–9.
Feixas F, Lindert S, Sinko W, McCammon JA. Exploring the role of receptor flexibility in structure-based drug discovery. Biophys Chem. 2014; 186:31–45.
Kukol A. Consensus virtual screening approaches to predict protein ligands. Eur J Med Chem. 2011; 46(9):4661–4.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000; 28(1):235–42.
Wang R, Fang X, Lu Y, Yang C-Y, Wang S. The PDBbind database: Methodologies and updates. J Med Chem. 2005; 48(12):4111–9.
Liu Z, Li Y, Han L, Li J, Liu J, Zhao Z, Nie W, Liu Y, Wang R. PDB-wide collection of binding data: Current status of the PDBbind database. Bioinformatics. 2015; 31(3):405–12.
Towns J, Cockerill T, Dahan M, Foster I, Gaither K, Grimshaw A, Hazlewood V, Lathrop S, Lifka D, Peterson GD, Roskies R, Scott JR, Wilkins-Diehr N. XSEDE: Accelerating scientific discovery. Comput Sci Eng. 2014; 16(5):62–74.